[Form 4] Aptevo Therapeutics Inc Insider Trading Activity
Abdun-Nabi Daniel, identified as a director of Aptevo Therapeutics, reported the grant of 7,200 Restricted Stock Units (RSUs) with a transaction date of 08/06/2025. The filing states the RSUs convert one-for-one into common stock of the issuer.
The RSUs are reported as directly owned following the grant and are set to vest in full on the first anniversary of the grant date. The Form 4 shows no sale or disposition associated with this reported transaction and lists beneficial ownership after the transaction as 7,200 shares (upon conversion).
Abdun-Nabi Daniel, identificato come amministratore di Aptevo Therapeutics, ha dichiarato l'assegnazione di 7.200 Restricted Stock Units (RSU) con data dell'operazione 08/06/2025. Il documento specifica che le RSU si convertiranno con rapporto uno a uno in azioni ordinarie dell'emittente.
Le RSU risultano essere di propriet脿 diretta alla data dell'assegnazione e sono previste per vestire per intero al primo anniversario della data di concessione. Il Modulo 4 non riporta alcuna cessione o vendita relativa a questa transazione e indica la propriet脿 beneficiaria successiva pari a 7.200 azioni (al momento della conversione).
Abdun-Nabi Daniel, identificado como director de Aptevo Therapeutics, notific贸 la concesi贸n de 7.200 Unidades de Acciones Restringidas (RSU) con fecha de la operaci贸n 08/06/2025. El formulario indica que las RSU se convertir谩n uno a uno en acciones ordinarias del emisor.
Las RSU se registran como propiedad directa tras la concesi贸n y est谩n programadas para consolidarse en su totalidad en el primer aniversario de la fecha de concesi贸n. El Formulario 4 no muestra ninguna venta o disposici贸n relacionada con esta transacci贸n y enumera la propiedad beneficiaria tras la operaci贸n como 7.200 acciones (al convertirse).
Abdun-Nabi Daniel鞚� Aptevo Therapeutics鞚� 鞚挫偓搿� 鞁濍硠霅橃柎 7,200臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 08/06/2025 瓯半灅鞚检瀽搿� 攵�鞐皼鞎橂嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 RSU臧� 氚滍枆靷潣 氤错喌欤茧 1雽�1 牍勳湪搿� 鞝勴櫂霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 RSU電� 攵�鞐� 鞁滌爯鞐� 歆侅为 氤挫湢搿� 氤搓碃霅橃棃鞙茧┌, 攵�鞐澕搿滊秬韯� 觳� 氩堨Ц 旮半厫鞚检棎 鞝勳暋 氩犾姢韺�霅� 鞓堨爼鞛呺媹雼�. Form 4鞐愲姅 鞚� 瓯半灅鞕� 甏�霠悳 韺愲Г 霕愲姅 觳橂秳 雮挫棴鞚� 鞐嗢溂氅�, 瓯半灅 頉� 靾橅槣鞝� 靻岇湢甓岇潃 鞝勴櫂 鞁� 7,200欤�搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Abdun-Nabi Daniel, identifi茅 comme administrateur d'Aptevo Therapeutics, a d茅clar茅 l'octroi de 7 200 unit茅s d'actions restreintes (RSU) avec une date de transaction le 08/06/2025. Le dossier pr茅cise que les RSU seront converties au taux d'un pour un en actions ordinaires de l'茅metteur.
Les RSU sont indiqu茅es comme d茅tenues directement apr猫s l'attribution et doivent 锚tre acquises en totalit茅 au premier anniversaire de la date d'attribution. Le formulaire 4 ne signale aucune cession ou vente li茅e 脿 cette op茅ration et indique la d茅tention b茅n茅ficiaire apr猫s la transaction comme 7 200 actions (apr猫s conversion).
Abdun-Nabi Daniel, als Direktor von Aptevo Therapeutics angegeben, meldete die Gew盲hrung von 7.200 Restricted Stock Units (RSUs) mit Transaktionsdatum 08/06/2025. Die Einreichung besagt, dass die RSUs eins zu eins in Stammaktien des Emittenten umgewandelt werden.
Die RSUs werden nach der Gew盲hrung als direkt gehalten gemeldet und sollen am ersten Jahrestag des Gew盲hrungsdatums vollst盲ndig vesten. Das Formular 4 weist keine Ver盲u脽erung oder sonstige Disposition im Zusammenhang mit dieser Transaktion aus und listet das wirtschaftliche Eigentum nach der Transaktion mit 7.200 Aktien (bei Umwandlung).
- Grant of 7,200 RSUs to a director, with explicit 1:1 conversion into common stock and a clear vesting schedule (vests in full on first anniversary)
- None.
Insights
TL;DR: Director grant of 7,200 RSUs vesting in one year; routine compensation disclosure with limited immediate market impact.
The Form 4 documents a standard equity-based compensation grant to a director: 7,200 RSUs that convert 1:1 into common shares and vest in full after one year. This is presented as direct ownership after the grant and contains no sale or disposition data. From a compensation perspective, the award follows common practice of time-based vesting to tie future value to continued service and company performance.
TL;DR: Governance filing shows a typical director equity award; disclosure is complete on vesting schedule and conversion terms.
The filing clearly states the nature of the derivative award (RSUs), the conversion ratio (1:1), and that the RSUs vest in full on the first anniversary of grant. It also reports the post-transaction beneficial ownership as 7,200 shares. There are no indications in the form of dispositions, pledges, or indirect ownership claims related to these RSUs, so the disclosure is straightforward and specific to this grant.
Abdun-Nabi Daniel, identificato come amministratore di Aptevo Therapeutics, ha dichiarato l'assegnazione di 7.200 Restricted Stock Units (RSU) con data dell'operazione 08/06/2025. Il documento specifica che le RSU si convertiranno con rapporto uno a uno in azioni ordinarie dell'emittente.
Le RSU risultano essere di propriet脿 diretta alla data dell'assegnazione e sono previste per vestire per intero al primo anniversario della data di concessione. Il Modulo 4 non riporta alcuna cessione o vendita relativa a questa transazione e indica la propriet脿 beneficiaria successiva pari a 7.200 azioni (al momento della conversione).
Abdun-Nabi Daniel, identificado como director de Aptevo Therapeutics, notific贸 la concesi贸n de 7.200 Unidades de Acciones Restringidas (RSU) con fecha de la operaci贸n 08/06/2025. El formulario indica que las RSU se convertir谩n uno a uno en acciones ordinarias del emisor.
Las RSU se registran como propiedad directa tras la concesi贸n y est谩n programadas para consolidarse en su totalidad en el primer aniversario de la fecha de concesi贸n. El Formulario 4 no muestra ninguna venta o disposici贸n relacionada con esta transacci贸n y enumera la propiedad beneficiaria tras la operaci贸n como 7.200 acciones (al convertirse).
Abdun-Nabi Daniel鞚� Aptevo Therapeutics鞚� 鞚挫偓搿� 鞁濍硠霅橃柎 7,200臧滌潣 鞝滍暅攵� 欤检嫕 雼渼(RSU)毳� 08/06/2025 瓯半灅鞚检瀽搿� 攵�鞐皼鞎橂嫟瓿� 氤搓碃頄堨姷雼堧嫟. 鞝滌稖靹滊鞐愲姅 RSU臧� 氚滍枆靷潣 氤错喌欤茧 1雽�1 牍勳湪搿� 鞝勴櫂霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
頃措嫻 RSU電� 攵�鞐� 鞁滌爯鞐� 歆侅为 氤挫湢搿� 氤搓碃霅橃棃鞙茧┌, 攵�鞐澕搿滊秬韯� 觳� 氩堨Ц 旮半厫鞚检棎 鞝勳暋 氩犾姢韺�霅� 鞓堨爼鞛呺媹雼�. Form 4鞐愲姅 鞚� 瓯半灅鞕� 甏�霠悳 韺愲Г 霕愲姅 觳橂秳 雮挫棴鞚� 鞐嗢溂氅�, 瓯半灅 頉� 靾橅槣鞝� 靻岇湢甓岇潃 鞝勴櫂 鞁� 7,200欤�搿� 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Abdun-Nabi Daniel, identifi茅 comme administrateur d'Aptevo Therapeutics, a d茅clar茅 l'octroi de 7 200 unit茅s d'actions restreintes (RSU) avec une date de transaction le 08/06/2025. Le dossier pr茅cise que les RSU seront converties au taux d'un pour un en actions ordinaires de l'茅metteur.
Les RSU sont indiqu茅es comme d茅tenues directement apr猫s l'attribution et doivent 锚tre acquises en totalit茅 au premier anniversaire de la date d'attribution. Le formulaire 4 ne signale aucune cession ou vente li茅e 脿 cette op茅ration et indique la d茅tention b茅n茅ficiaire apr猫s la transaction comme 7 200 actions (apr猫s conversion).
Abdun-Nabi Daniel, als Direktor von Aptevo Therapeutics angegeben, meldete die Gew盲hrung von 7.200 Restricted Stock Units (RSUs) mit Transaktionsdatum 08/06/2025. Die Einreichung besagt, dass die RSUs eins zu eins in Stammaktien des Emittenten umgewandelt werden.
Die RSUs werden nach der Gew盲hrung als direkt gehalten gemeldet und sollen am ersten Jahrestag des Gew盲hrungsdatums vollst盲ndig vesten. Das Formular 4 weist keine Ver盲u脽erung oder sonstige Disposition im Zusammenhang mit dieser Transaktion aus und listet das wirtschaftliche Eigentum nach der Transaktion mit 7.200 Aktien (bei Umwandlung).
FAQ
What did the Form 4 for Aptevo (APVO) report?
How do the RSUs reported by APVO convert to common stock?
When do the 7,200 RSUs vest according to the filing?
Does the Form 4 show any sale or disposition of shares by the reporting person?
What ownership form is listed for the RSUs in the filing?
